Pfizer gets US FDA approval for Panzyga to treat rare neurological disease
Panzyga was previously approved in the US to treat primary humoral immunodeficiency in people aged two years and…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
15 Feb 21
Panzyga was previously approved in the US to treat primary humoral immunodeficiency in people aged two years and…
15 Feb 21
The EC approval allows the sale of Ogluo in all 27 European Union (EU) member countries, along with…
10 Feb 21
Bamlanivimab plus etesevimab combination is indicated for the treatment of mild to moderate Covid-19 in patients aged 12…
09 Feb 21
Asciminib is an investigational STAMP inhibitor, currently under development across multiple treatment lines of acute myeloid syndrome
08 Feb 21
Breyanzi demonstrated a 73% overall response rate and 54% complete response (CR) rate in TRANSCEND NHL 001 trial
05 Feb 21
The drugmaker claims that Forxiga is the first SGLT2 inhibitor approved in China to treat heart failure with…
02 Feb 21
Plegridy intramuscular injection offers a treatment option with reduced injection site reactions for individuals with relapsing multiple sclerosis…
27 Jan 21
AstraZeneca said its Symbicort Turbuhaler is the first approved dual-combination therapy for mild, moderate and severe asthma in…
25 Jan 21
The FDA approval of the combination regimen is based on the results of the phase 3 CheckMate -9ER…
25 Jan 21
Pfizer and BioNTech's Covid-19 vaccine has been provisionally approved for individuals aged 16 years and above